Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02339324
Title Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pittsburgh
Indications

melanoma

Therapies

Interferon alpha-2b

Pembrolizumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field